Derek Yung
Analyst · RBC Capital Markets. Your line is open
Thanks Scott, and good afternoon everyone. Our first quarter financial results reflect underlying strength of our platform and continued strong execution in our Medicare business, despite the challenging public safety and related macroeconomic environment. We entered the year on a strong note with a first quarter Medicare revenue of $96.2 million, growing 75% compared to a year-ago, driven by a 46% increase in approved Medicare members, 86% growth in non-commission revenue as well as an increase in residual or [tell] (Ph) revenue recognized during the quarter. The Medicare segment generated a profit of $22 million, an increase of 103%, compared to the first quarter of 2019. The open enrollment period was particularly important contributor to our first quarter Medicare enrollments this year with Medicare Advantage approved members growing 59%, compared to your first quarter a year-ago. Medicare Advantage enrollments attributable to the open enrollment period represented a larger percentage of our total approved Medicare members, compared to first quarter of 2019. Our estimated number of revenue generating Medicare members was approximately 726,000 at the end of the first quarter on increase of 44%, compared to a year-ago. Similar to a year-ago, we saw an increase in Medicare Advantage member churn to above average levels during the first quarter. It was driven primarily by higher than average attrition rates into cohort that we enrolled during the last AEP in Q4 of 2019. As you recall, we observed a similar increase in Q1 of last year which was followed by a decline in member churn in subsequent quarters. We believe that this new seasonal patterns of consumer behavior is due to their introduction of the open enrollment period in 2019 and that seniors will optimize their plan during the first quarter, a less likely to churn later in the year. The churn is likely to be even more pronounced this year as more seniors took advantage of the open enrollment period on our platform compared to a year-ago. We currently expect for churn to decline later in the year as it was the case in 2019 and continue to forecast 2020 Medicare Advantage lifetime values to be roughly flat with last year's. It is also important to note that churning our member base is highest in year one and declined significantly in subsequent years. For example, our average first year churn for a Medicare Advantage member is in the mid-thirties that decline to just under 20% in year two and then again to 11% year three. In year four and beyond churn rates have dropped to single digits. As a result in periods of high growth when new members represent a larger percentage of our total member base, we see a higher total implied churn. We have provided our historical average churn rates by year as part of our first quarter 2020 earnings slide posted on our investor relations website. First quarter constrained lifetime values of our Medicare Advantage product grew 5% year-over-year due primarily to an increase in average commission payments per member. As a reminder, our constraint LTVs are derived by applying a constraint factor through statistical estimates of expected lifetime commission received. We are effectively discounting the revenue we booked compared to what we expect to collect. Since the adoption of ASC606 for revenue recognition, our cash collections from Medicare Advantage plans have generally exceeded initial estimates reflecting the appropriate conservatism of our approach. This dynamics has contributed to the recognition of residual or tail revenue for Medicare Advantage members in every quarter in 2019 and again in Q1 of 2020. I would like to note that beginning with this quarter Q1 of 2020 we will be reporting the number of new paying members added during the quarter with the goal of providing additional transparency into our membership dynamics. The Delta between approved members and new paying members access because not all prove out applications result in an active policy for various reasons. For a given period this conversion rate also is impacted by the lag between the time an application gets approved by high carrier and we will receive the commission payments for that possibly as we count an applicant as a new paying member when we receive the commission payments. For example, in the first quarter of 2020 we had 85,000 approved Medicare members and added 161,500 new paying members reflecting a significant spillover of enrollments from Q4 of 2019. The difference between the two metrics tend to be especially pronounced in the first and fourth quarters, given the large number of enrollments to prove during the annual enrollment period in the fourth quarter, do not start generating commissions until the first quarter when these plans become effective. Turning to our individual family and small business segment, first quarter revenue from this segment was 10.3 million a 26% decline compared to a year-ago. This was driven by lower IFP enrollments and tail revenue compared to a year-ago, partially offset by increase in short-term and small business group commissions. The individual family small business segment remained a profitable standalone business for the first quarter, generating segment profit of $2.6 million, compared to $6 million in the first quarter of 2019. Our estimated individual and family plan membership at the end of the first quarter was approximately 113,000 down 13% compared to estimated membership reported at the first quarter a year-ago. The estimated number of members on small business products was approximately 44,000 a 3% increase compared to a year-ago. Our total revenue for the first quarter was $106.4 million, an increase of 55% compared to the first quarter of 2019. Our total estimated membership at the end of the quarter for all products combined was approximately 1,137,000 members. Now I would like to review our operating expenses and profitability metrics. First quarter operating expenses reflect a higher run rate in fixed costs as we scaled our business in the second half of 2019 in preparation for our annual open enrollment period. We anticipate year-over-year growth rates in G&A and technology and contents spend to start normalizing in the third quarter. For the full-year 2020, we expect to see the fixed costs leverage resulting in margin expansion relative to 2019. The overall variable cost - acquisition cost per approved Medicare member which includes marketing and customer care related spends increased by 5% year-over-year. Underneath that variable call center cost per approved Medicare member grew 6% year-over-year as we retain a larger number of agents fall into Annual Enrollment Period compared to last year. This increase also reflect costs associated with moving our call center to remote model in March in light of the Corona Virus crisis. Marketing costs per approved member grew 5% primarily reflecting a shift in channel mix with a continuing increase in enrollment volumes coming from our digital advertising channels, and the decline in contribution from some of our partners that pull back on marketing initiatives in this environment. For the full-year 2020, we continue to expect that total variable acquisition cost per approved Medicare member will come down to 2019 levels driven primarily by further gains in agent productivity. GAAP net income for the first quarter of 2020 was $3.5 million compared to GAAP net loss of $5.2 million for the first quarter of 2019. Adjusted EBITDA for the first quarter of 2018 was $11.1 million, compared to $8.6 million for the first quarter 2019. We calculate adjusted EBITDA by adding stock based compensation, change in fair value of earn out liability, depreciation, amortization, amortization intangible assets, other incomes and benefits for income taxes to our GAAP net income. Our first Quarter cash flow from operations was $8.9 million, compared to $12.7 million for the first quarter of 2019. Capital expenditures, which include capitalized internally developed software costs were approximately $6.1 million for the first quarter. As of March 31st we had 246 million in cash, cash equivalents and marketable securities, and we had no debt outstanding under a line of credit. Our balance sheet also reflect a significant commissions receivable balance of approximately $560 million that is comprised of $125 million dollars expected collected over the next 12-months and $435 million in long term commissions receivable. We are updating our 2020 annual guidance to reflect our outperformance to-date, and an increase in our diluted share accounts following the equity offering that we completed in March. As Scott mentioned, this guidance does not reflect our full investment plan for the upcoming AEP as a result of the increased working capital provided by the offering. We are now forecasting revenues for 2020 to be in a range of $600 million to $640 million, compared to the prior guidance of range of $580 million to $620 million. Medicare segment revenues are now expected to be in a range of $553 million to $589 million, compared to prior guidance of $533 million to $569 million. Individual, family and small business segments revenue is expected to be in a range of $47 to $51 million, which is unchanged compared to prior guidance. We expect GAAP net income for 2020 to be in a range of $70 million to $85 million, compared to the prior guidance range of $68 million to $83 million. We expect 2020 adjusted EBITDA to be in a range of $125 million to $140 million, compared to prior guidance range of $120 million to $135 million. 2020 Medicare segment profit is now expected to be in a range of $157 million to $174 million, compared to the prior guidance range of $152 million to $169 million. Individual, family and small business segment profit is expected to be in a range of $17 million to $18 million, which is unchanged compared to product guidance. Guidance were corporate services expenses excluding stock-based compensation and depreciation and amortization expenses remains unchanged at approximately $49 million to $52 million. GAAP net income per diluted share for 2020 is expected to be in a range of $2.55 to $3.10, compared to prior guidance of $2.64 to $3.23 per share. Non-gap net income per diluted share for 2020 is expected to be in a range of $3.41 to $3.90, compared to prior guidance range of $3.56 to $4.09 per share. Cash used in operations for 2020 is now expected to be in a range of $61 million to $64 million, compared to prior guidance range of $52 million to $55 million. Cash used for capital expenditures is expected to be $18 million to $20 million, which is unchanged from prior guidance. Finally, I would like to comment on sequential trends. Consistent with previous seasonality trends, the second and third quarter Medicare enrollment volumes are at the lowest points compared to other times of the year. Last year, our year-over-year growth in the second quarter was aided by a particularly week comparison period in 2018 that included the closure of our Westford Massachusetts sales center in May of 2018. While we expect year-over-year growth in the second quarter to remain strong, the rate of increase would not benefit to the same degree due to just weaker comparison period Q2 of last year. Second quarter [tel] (Ph) revenue is also expected to decline sequentially. Similar to last year, we will be retaining the majority of our in-healthy agents posts OEP, which is expected to result in a further increase in agent productivity during the critical selling season in Q4, but is adding to our cost base during the lower volume second and third quarters. As a result, we currently expect the second quarter revenue growth to be approximately 20% on a year-over-year basis and we expect our adjusted EBITDA loss in a mid single-digit millions of dollars for the quarter. We continue to refine our sales and marketing investment plans for the fourth quarter and expect to finalize those plans over the rest of this quarter. We plan to provide further updated guidance for 2020 that includes the anticipated results of those investments as well as an updated five-year outlook at the time of our second quarter earnings report. I want to remind you that these comments in our guidelines are based on current inductions of our business and our current estimates, assumptions and judgments which may change at any time, our actual results may differ as a result of changes in our estimates, assumptions and judgments we undertake no obligation to update our comments or our guidance. I would now like to turn back to Scott's who will make some short closing remarks and then open up call for questions. Scott.